Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children and adolescents aged 1 to 17 years at diagnostic~* Documented Ph+ ALL~* Eligibility for the current local prospective therapeutic study of childhood ALL~* Informed consent given by the parents or by legal guardian~Exclusion Criteria:~* Abnormal hepatic functions~* Abnormal renal functions~* Active systemic bacterial, fungal or viral infection

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Good risk Ph+ALL (Type: OTHER): For protocols which adopt a steroid prephase: patients who are Prednisone-good responder and achieve CR after the induction course. For protocols which do not adopt steroid prephase: patients who have M1/M2 BM at day 15 or M1 BM at day 21 and achieve CR after the induction course. Expected stratification in this group: 70-75%.
- Poor risk Ph+ALL (Type: OTHER): For protocols which adopt a steroid prephase: patients who are Prednisone poor-responders. For protocol which do not adopt a steroid prephase: patients who have M3 BM at day 15 or M2/M3 BM at day 21. For all protocols: patients who do not achieve CR after the induction course. Expected stratification: 25-30%.

Based on this trial design, predict the completion outcome and termination type (if applicable).